Can a Smartphone App Prevent Depression? The HeadGear Trial

A smartphone app may help prevent depression in working adults—but the best result comes from one trial, on a secondary outcome, under conditions that real-world app users rarely sustain.

That trial measured something more useful than a small shift on a symptom questionnaire: whether participants developed depression over the following year. In Deady et al.'s HeadGear randomized trial, the app group had lower odds of incident depression at 12 months than an active mood-monitoring control group (odds ratio 0.43; 95% CI, 0.26–0.70; p=0.001). The estimated absolute risk reduction was about 4.5 percentage points, or roughly one fewer case for every 22 workers offered the intervention for a year.

That is a clinically meaningful endpoint. It does not prove that every mindfulness app prevents depression, nor does it make HeadGear a substitute for sleep, exercise, treatment, or a functional workplace. It does justify taking a well-designed behavioral app more seriously than the usual digital-wellness wallpaper.

A prevention trial with a real clinical endpoint

HeadGear enrolled 2,271 employed Australian adults who did not have current depression. Researchers randomly assigned them to a self-directed smartphone program built around behavioral activation and mindfulness, or to a 30-day mood-monitoring app. Behavioral activation asks people to schedule and do worthwhile activities even when motivation has gone missing; mindfulness exercises aim to change how people respond to thoughts and feelings. The comparison app was active, not a no-treatment control.

At 12 months, the incidence result favored HeadGear. An odds ratio of 0.43 means the app group had lower odds of developing depression than the monitoring group, and the confidence interval did not include no difference. The approximate number needed to treat, 22, puts the relative result into practical terms: the estimated benefit was modest in absolute terms, but potentially consequential across a workforce.

Most app trials emphasize symptom scales over short follow-up periods. Symptoms matter, but preventing a new depressive episode is a harder outcome to move and easier for readers, clinicians, and employers to interpret. That makes this finding unusually relevant. It also raises the standard for skepticism.

The main result was not the primary result

The study's prespecified primary outcome was continuous PHQ-9 depression score at three months. It met conventional statistical significance only narrowly: F_3,734.7=2.98 and p=0.031. The reported statistic corresponds to an estimated Cohen's d of about 0.22, a small difference. Statistical significance answers whether the observed difference is difficult to explain by chance under the study model; it does not tell us whether the change was large enough for a participant to notice in daily life.

The 12-month incident-depression outcome produced the more compelling result, but it was secondary. Secondary findings can be real, especially when they are precise and clinically relevant. They still need replication before they should drive broad claims about prevention. The trial authors also cautioned readers about the small symptom effect and attrition.

Attrition is not a bookkeeping nuisance in app research. It can change the answer. The mixed-model analysis assumes missing data are missing at random, an assumption that cannot be verified from the published abstract. If people who developed early symptoms were more likely to stop answering follow-up surveys in one group than the other, the apparent prevention effect could be biased.

That concern fits a broader engagement problem. A 2025 Brighten Study analysis found that early nonadherence strongly predicted later dropout among adults using a digital mental-health app. Most users disengaged before completing the protocol. HeadGear's estimated NNT of 22 reflects trial conditions; a workplace rollout with lower completion rates would probably prevent fewer cases per person offered the app.

An active comparator complicates the interpretation

HeadGear did not beat an empty screen. It beat a mood-monitoring app, which is a reasonable way to control for attention and smartphone use but leaves a practical question: could monitoring mood itself help some people respond earlier to worsening symptoms?

A 2024 systematic review of digital phenotyping found that smartphone behavioral data can help identify early stress, anxiety, and mild depression. Detection is not treatment, and that review does not show that mood monitoring prevents depression. Still, the control app may have had some value of its own. If it did, HeadGear's result estimates the added value of behavioral activation plus mindfulness over monitoring, not the difference between HeadGear and doing nothing.

This does not invalidate the trial. It narrows what the trial can answer. It also means the most useful future study would replicate incident-depression prevention with careful retention analysis and a comparator that clarifies how much benefit comes from monitoring, structured behavior change, or both.

What the rest of the literature can—and cannot—add

Other digital interventions support the general idea that structured online mental-health programs can improve symptoms in employed or high-stress groups, but they do not replicate HeadGear's incident-depression result.

For people with insomnia and elevated depression risk, Leerssen et al. tested therapist-guided digital cognitive behavioral therapy plus circadian-rhythm support in a randomized trial. The intervention prevented worsening depressive symptoms. This is encouraging for insomnia-linked risk, but it was more intensive than HeadGear, included therapist guidance, and targeted a higher-risk population. Its result cannot be converted into a comparable NNT for generally healthy workers.

A 2024 systematic review in hospital nurses also found mental-health and well-being benefits from mHealth apps, while identifying engagement and usability as recurring barriers. A randomized Peruvian university-community trial reported lower depression, anxiety, and stress scores with a self-administered digital intervention. These results extend symptom-level evidence across settings, but neither study establishes prevention of new depression cases in a general employed population.

Component testing matters, too. A 2025 factorial study in healthcare workers examined which elements of a preventive stress-management app contributed to outcomes. That design reflects an inconvenient truth about app bundles: a package can work without every feature earning its place. HeadGear combined behavioral activation and mindfulness, so this trial cannot identify which component, if either, drove its incidence finding.

Build prevention around the better-replicated basics

Exercise has a broader and more replicated evidence base than any specific mental-health app. A 2024 meta-analysis of 48 randomized trials found several exercise modalities effective for preventing and treating perinatal depression. Evidence in other populations points in the same direction, though effect sizes and applicability vary. A walking meta-analysis involved postpartum participants with mild-to-moderate depression, not general workers, and a network meta-analysis focused on adolescents with depression. Those studies support exercise as a sensible foundation; they do not supply a head-to-head comparison with HeadGear.

Dietary and microbiome approaches deserve more restrained language. A 2026 meta-analysis in healthy working adults found that probiotics may improve depression, anxiety, stress, sleep, and related outcomes. A broader 2025 meta-analysis in patients with depression reported improved depressive symptoms with microbiome-targeted treatments (standardized mean difference −0.26; 95% CI, −0.32 to −0.19), with moderate heterogeneity. These are symptom findings, not proof of prevention in healthy workers.

The literature is also uneven. A 2024 meta-analysis of five pediatric probiotic trials, involving 692 participants, found no overall improvement in depressive symptoms (SMD 0.04; 95% CI, −0.33 to 0.41; p=0.84). That null result does not settle the question for adults, but it argues against treating probiotics as a dependable antidepressant in a capsule.

A two-year Mediterranean-diet trial in people recovered from depression found no difference in depression recurrence, its primary outcome, although the dietary group improved on secondary depressive-symptom measures. The distinction matters: lower symptom burden and fewer recurrent episodes are related outcomes, not interchangeable ones.

Verdict

HeadGear offers a credible, low-risk addition for nondepressed workers who will actually use it. Its 12-month finding—about 4.5 fewer depression cases per 100 people offered the app, with an estimated NNT of 22—is one of the more clinically relevant results in digital mental-health research.

But the result rests on one study, a secondary endpoint, substantial follow-up concerns, and engagement patterns that usually deteriorate outside trials. Use a behavioral app as an adjunct, especially if it helps you maintain routines and notice early trouble. Put exercise, adequate sleep, social connection, and timely professional care ahead of any app subscription. For workers with insomnia and elevated depression risk, the evidence favors a more targeted, guided digital CBT and circadian approach over hoping a generic wellness app will do the whole job.